CLINICAL-SIGNIFICANCE OF CATHEPSIN-D IN PRIMARY OVARIAN-CANCER

被引:29
作者
SCAMBIA, G [1 ]
PANICI, PB [1 ]
FERRANDINA, G [1 ]
SALERNO, G [1 ]
DAGOSTINO, G [1 ]
DISTEFANO, M [1 ]
DEVINCENZO, R [1 ]
ERCOLI, A [1 ]
MANCUSO, S [1 ]
机构
[1] UNIV CATTOLICA SACRO CUORE, DEPT GYNECOL & OBSTET, I-00168 ROME, ITALY
关键词
CATHEPSIN D; OVARIAN CANCER; PROGNOSIS;
D O I
10.1016/0959-8049(94)90118-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cathepsin D (Cath D) levels were assayed in a prospective series of 72 patients with primary ovarian carcinoma, by using an immunoradiometric assay. Cath D levels ranged from 2.00 to 45.60 pmol/mg protein with a median value of 15.80 pmol/mg protein. Cath D levels were higher in metastatic deposits than in primary tumors (median 24.12, range 9.33-98.33 pmol/mg protein versus median 12.76, range 2.00-45.20 pmol/mg protein; P = 0.04). The cut-off Levels of the lower, median and upper quartiles of the distribution of Cath D were identified to distinguish patients with low, intermediate, and high Cath D content. Cases with low Cath D content showed a lower percentage of complete response to chemotherapy than cases with intermediate and high Cath D content (22% versus 65% and 47%, respectively) (P = 0.003). Moreover cases with high Cath D content showed a worse prognosis with respect to patients with intermediate Cath D levels (P = 0.09). Interestingly, cases with low Cath D content had a shorter progression-free survival with respect to cases with intermediate Cath D content (P = 0.04). Cath D status retained an independent prognostic value when assessed in the multivariate analysis
引用
收藏
页码:935 / 940
页数:6
相关论文
共 30 条
[1]   EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN-BREAST CANCER - CORRELATION WITH STEROID-HORMONE RECEPTORS AND AXILLARY LYMPH-NODE INVOLVEMENT [J].
BATTAGLIA, F ;
SCAMBIA, G ;
ROSSI, S ;
PANICI, PB ;
BELLANTONE, R ;
POLIZZI, G ;
QUERZOLI, P ;
NEGRINI, R ;
IACOBELLI, S ;
CRUCITTI, F ;
MANCUSO, S .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (11) :1685-1690
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   CATHEPSIN D ASSAY IN PRIMARY BREAST-CANCER AND LYMPH-NODES - RELATIONSHIP WITH C-MYC, C-ERB-B-2 AND INT-2 ONCOGENE AMPLIFICATION AND NODE INVASIVENESS [J].
BROUILLET, JP ;
THEILLET, C ;
MAUDELONDE, T ;
DEFRENNE, A ;
SIMONYLAFONTAINE, J ;
SERTOUR, J ;
PUJOL, H ;
JEANTEUR, P ;
ROCHEFORT, H .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (04) :437-441
[4]   ESTRADIOL INCREASES THE SECRETION BY MCF7 CELLS OF SEVERAL LYSOSOMAL PROENZYMES [J].
CAPONY, F ;
ROUGEOT, C ;
CAVAILLES, V ;
ROCHEFORT, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 171 (03) :972-978
[5]   ESTROGENS AND GROWTH-FACTORS INDUCE THE MESSENGER-RNA OF THE 52K-PRO-CATHEPSIN-D SECRETED BY BREAST-CANCER CELLS [J].
CAVAILLES, V ;
AUGEREAU, P ;
GARCIA, M ;
ROCHEFORT, H .
NUCLEIC ACIDS RESEARCH, 1988, 16 (05) :1903-1919
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   ESTRADIOL STIMULATES CELL-GROWTH AND SECRETION OF PROCATHEPSIN-D AND A 120-KILODALTON PROTEIN IN THE HUMAN OVARIAN-CANCER CELL-LINE BG-1 [J].
GALTIERDEREURE, F ;
CAPONY, F ;
MAUDELONDE, T ;
ROCHEFORT, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (06) :1497-1502
[8]  
GARCIA M, 1990, ONCOGENE, V5, P1809
[9]  
GOLDFARB RH, 1986, MECHANISMS CANCER ME, P341
[10]  
HENRY JA, 1990, CANCER, V65, P265, DOI 10.1002/1097-0142(19900115)65:2<265::AID-CNCR2820650214>3.0.CO